

15th European Multiple Myeloma Academy

27th – 28th January 2017

SCIENTIFIC PROGRAM

Thursday, 26th January 2017

DINNER BUFFET MEETING (limited access, registration required)

19.30 - 20.45 **When to start treatment at relapse**
Joan Bladé

Friday, 27th January 2017

GRAND CONFERENCE ROOM

- 8.15 - 8.20 **Welcome**
Heinz Ludwig and Jesus San Miguel
- 8.20 - 8.45 **Molecular pathogenesis of multiple myeloma**
Brian Walker
- 8.45 - 9.10 **The role of the microenvironment during MGUS myeloma transformation**
Irene M. Ghobrial
- 9.10 - 9.35 **Copy number alterations, FISH and mutations in myeloma associated with outcome**
Herve Avet-Loiseau
- 9.35 - 10.05 **Expert discussion: Bringing the evolving wealth of information into perspective**
Moderator: *Jesus San Miguel*
Participants: *Brian Walker, Irene Ghobrial, Herve Avet-Loiseau*
- Which research area most likely will advance our understanding of myeloma initiation?
 - FISH and gene expression – what comes next?
 - Can mutation analysis be used for clinical management?
 - Questions from audience

- 10.05 - 10.35** **Coffee Break**
- 10.35 - 11.45** **Workshops**
- Pathophysiology and Management of myeloma bone disease
David Roodman
 - Treatment of extramedullary myeloma plasma cell leukemia
Joan Bladé
 - Myeloma emergencies (Infections, acute renal impairment, hypercalcemia and spinal cord compression)
Heinz Ludwig
- 11.45 - 12. 15** **Keynote Lecture: Can multiple myeloma be a curable disease?:
Actions to achieve this goal**
Jesus San Miguel
- 12.15 - 13.15** **Lunch Buffet**
- 13.15 - 13.40** **MRD assessment: Comparison of techniques and clinical relevance**
Bruno Paiva
- 13.40 - 14. 10** **Expert discussion: MRD assessment - ready for prime time?**
Moderator: *Herve Avet-Loisseau*
Participants: *Bruno Paiva, Irene Ghobrial, Jesus San Miguel*
- Is PET/CT sensitive enough for detection of residual MM sites?
 - The patient achieved MRD negativity: What are the consequences?
 - Is liquid biopsy an option in MM?
 - Questions from the audience
- 14.10 -15.20** **Workshops**
- 15.20 - 15.50** **Coffee Break**
- 15.50 - 16.15** **Imaging of myeloma bone disease**
Jens Hillengaß
- 16.15 - 16.40** **Management of MGUS and smoldering multiple myeloma**
Sigurdur Kristinsson
- 16.40 - 17.05** **Management of transplant eligible patients in 2017**
Philippe Moreau

- 17.05 - 17.35** **Expert discussion: Frontline therapy in the young fit patient**
Moderator: *Philippe Moreau*
Participants: *Irene Ghobrial, Sigurdur Kristinsson, Jens Hillengaß*
- How to improve induction therapy?
 - Optimal approach in high-risk patients?
 - Maintenance after ASCT?
 - Strategies for patients not responding to induction?
 - Questions from the audience

19.00 **Departure to Delegate Dinner**

19.15 **Delegate Dinner**

Saturday, 28th January 2017

BREAKFAST MEETING (limited access, registration required)

- 7.30 - 8.30** **Management (ASCT) of difficult to treat patients**
(elderly, high cytogenetic risk, PCL, extramedullary disease and amyloidosis)
Mohamad Mohty

GRAND CONFERENCE ROOM

- 8.30 - 8.55** **What is new in the therapy of fit elderly patients**
Thierry Facon

- 8.55 - 9.20** **The best approach in unfit and frail patients**
Alessandra Larocca

- 9.20 - 9.45** **Sequencing in relapsed/refractory disease**
Heinz Ludwig

- 9.45 - 10.15** **Panel discussion: The difficult to treat patients - the frail and the relapsed patients**

Moderator: *Heinz Ludwig*

Participants: *Thierry Facon, Alessandra Larocca*

- What is the role of cytogenetics?
- Start slow with later dose increase?
- Discuss reasons for shorter relative survival in elderly
- Hit hard or hit sequentially in RR patients?
- Questions from the audience

- 10.15 - 10.45** **Coffee break**

- 10.45 - 11.05** **Antibodies as novel tools in myeloma therapy**
Niels van de Donk

- 11.05 - 11.25** **Novel immune therapies other than antibodies**
Hermann Einsele
- 11.25 - 11.45** **New (non-immunotherapy) drugs and new treatment strategies**
Pieter Sonneveld
- 11.45 - 12. 15** **Panel discussion: How to maximize the benefit of new developments?**
Moderator: *Pieter Sonneveld*
Participants: *Niels van de Donk, Hermann Einsele*
- Immunotherapy when and how long?
 - Immunotherapy combos?
 - The best strategy after failure to CD38 targeted therapy?
 - What can we expect from novel non-immunotherapy drugs?
 - Questions from the audience
- 12.15 - 12. 40** **New developments in amyloidosis**
Giampaolo Merlini
- 12.40 - 12.45** **Closure of the meeting**